This service is billed using CPT code 90791
At 10 mg/mL, 2.5 mg of tirzepatide equals 25 units on a U-100 insulin syringe
Composition Cagrilintide: 10 mg Appearance: lyophilized powder in a sealed research vial Research Focus (non-clinical) Peptide identity and purity assessment Assay development and calibration for quantitative analysis Chromatographic method optimization for impurity profiling Stability characterization of a lyophilized peptide under laboratory storage conditions Documentation Lot-specific COA available Batch and lot traceability Important Notice For research use only Not for human consumption Not intended to diagnose, treat, cure, or prevent any disease Quality & Manufacturing Lot-specific COA Lyophilized for transit stability
Similarly, compounds from the spiro-oxindole dihydroquinazolinone series identified in the screening, e.g., 42 are weak inhibitors and besides that not stable in in vitro assays
With injectable protocols, some patients report visible improvements in skin quality within 2-4 weeks
Cagrilintide is typically considered for: Adults with BMI 30 , or BMI 27 with a metabolic condition Patients who have plateaued on GLP-1 therapy Individuals with strong appetite, cravings, or binge-eating tendencies Those seeking an alternative to or enhancement of weight loss medications Who Should Avoid Cagrilintide
